Fibroblast Growth Factors (FGFs) are a family of growth factors which play an important role in tissue repair and regeneration. The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) signalling pathway fundamentally regulates embryogenesis, adult tissue homeostasis, angiogenesis and wound repair.

CPL304110 is a small molecule fibroblast growth factor receptor (FGFR) inhibitor being investigated as a potential targeted therapy for patients with FGFR aberrations suffering from gastric, bladder and lung cancer.

The main clinical trial purpose is to assess safety, tolerability, pharmacokinetic properties and safety profile of the novel CPL304110 compound when administered once daily to adults with advanced solid malignancies in 28-day cycles.

We would like to invite you to participate in the study named: "A Phase I, Open-label, Multicentre, Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects with Advanced Solid Malignancies". Results of this study will be used to further development of new Celon Pharma's oral drug used in oncology.